Related Experiment Video
Updated: Jun 17, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Progressive Systemic Sclerosis- from the molecular background to innovative therapies
1Institute of Immunology, Rikshospitalet, University of Oslo, Oslo, Norway. szodoray@gmail.com
Frontiers in Bioscience (Elite Edition)
|December 29, 2009
Summary
Systemic sclerosis (SSc) is an autoimmune disease involving vascular damage and fibrosis. This review details SSc pathogenesis, current therapies targeting these processes, and novel immune-modulating treatments.
Area of Science:
- Rheumatology
- Immunology
- Pathophysiology
Background:
- Systemic sclerosis (SSc) is a complex autoimmune disorder characterized by vascular damage, fibrogenesis, and immune system dysregulation.
- The pathogenesis involves intricate interactions between endothelial dysfunction, fibroblast activation, and aberrant immune responses.
Purpose of the Study:
- To elucidate the pathogenic mechanisms underlying Systemic sclerosis.
- To review current and investigational therapeutic strategies for SSc management.
Main Methods:
- Comprehensive literature review of SSc pathogenesis and treatment modalities.
- Analysis of established and emerging therapies targeting vascular, fibrotic, and autoimmune pathways.
Main Results:
- SSc pathogenesis is multifactorial, involving key processes like vascular injury, excessive collagen deposition (fibrosis), and autoimmune attacks.
- Therapeutic approaches aim to mitigate these core pathological features, with varying degrees of success.
Conclusions:
- Understanding SSc pathogenesis is crucial for developing effective treatments.
- Novel immunomodulatory therapies, including stem cell transplantation and photochemotherapy, offer promising avenues for SSc management.
Related Concept Videos
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...